Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 9/2015

01-11-2015 | Review

Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the ‘future’ in dermatology therapeutics?

Authors: Mrinal Gupta, Vikram K. Mahajan, Karaninder S. Mehta, Pushpinder S. Chauhan, Ritu Rawat

Published in: Archives of Dermatological Research | Issue 9/2015

Login to get access

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors and comprise three different isoforms namely PPARα, PPARγ, and PPARβ/δ with PPARβ/δ being the predominant subtype in human keratinocytes. After binding with specific ligands, PPARs regulate gene expression, cell growth and differentiation, apoptosis, inflammatory responses, and tumorogenesis. PPARs also modulate a wide variety of skin functions including keratinocyte proliferation, epidermal barrier formation, wound healing, melanocyte proliferation, and sebum production. Recent studies have shown the importance of PPARs in the pathogenesis of many dermatological disorders. Clinical trials have suggested possible role of PPAR agonists in the management of various dermatoses ranging from acne vulgaris, psoriasis, hirsutism, and lipodystrophy to cutaneous malignancies including melanoma. This article is intended to be a primer for dermatologists in their understanding of clinical relevance of PPARs and PPAR agonists in dermatology therapeutics.
Literature
1.
Abraham DJ, Eckes B, Rajkumar V, Krieg T (2007) New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 9:136–143PubMedCrossRef
2.
Amr K, Abdel-Hameed M, Sayed K, Nour-Edin F, Abdel Hay R (2014) The Pro12Ala polymorphism of the gene for peroxisome proliferator-activated receptor gamma is associated with a lower Global Acne Grading System score in patiemts with acne vulgaris. Clin Exp Dermatol 39:741–745PubMedCrossRef
3.
Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J et al (2000) Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133:263–274PubMedCrossRef
4.
Behshad R, Cooper KD, Korman NJ (2008) A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 144:84–88PubMedCrossRef
5.
Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U (2005) Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: an open-label pilot study. Rheumatology 44:126–129PubMedCrossRef
6.
Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne JP et al (2009) In vitro and in vivo anti-melanoma effects of ciglitazone. J Invest Dermatol 129:1208–1212PubMedCrossRef
7.
Braissant O, Wahli W (1998) Differential expression of peroxisome proliferator-activated receptor-alpha-beta, and -gamma during rat embryonic development. Endocrinology 139:2748–2754PubMed
8.
Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnnet M et al (2005) PPAR gamma agonists inhibit TGF-beta induced pulmonary myofibroblasts differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 288:L1146–L1153PubMedCrossRef
9.
10.
Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D et al (2004) No effect of Rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363:429–438PubMedCrossRef
11.
Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S (2007) A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 195:1754–1761PubMedCrossRef
12.
Chen W, Yang CC, Sheu HM, Seltmann H, Zouboulis CC (2003) Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol 121:441–447PubMedCrossRef
13.
Chiba T, Takeuchi S, Esaki H, Yamamura K, Kurihara K, Moroi Y et al (2012) Topical application of PPAR alpha (but not beta/delta or gamma) suppresses atopic dermatitis in NC/Nga mice. Allergy 67:936–942PubMedCrossRef
14.
Clark RB (2002) The role of PPARs in inflammation and immunity. J Leukoc Bio 71:388–400
15.
Coras B, Hafner C, Reichle A, Hohenleutner U, Szeimies RM, Landthaler M et al (2004) Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic Kaposi sarcoma. Arch Dermatol 140:1504–1507PubMedCrossRef
16.
17.
Dahten MS, Worm M (2007) PPAR gamma expression profile and its cytokine driven regulation in atopic dermatitis. Allergy 62:926–933PubMedCrossRef
18.
Demerjian M, Choi EH, Man S, Chang S, Elias PM, Feingold KR (2009) Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 18:643–649PubMedCentralPubMedCrossRef
19.
Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C (2005) Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 52:299–308PubMedCrossRef
20.
Di-Poi N, Michalik L, Desvergne B, Wahli W (2004) Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis. Lipids 39:1093–1099PubMedCrossRef
21.
Di-Poi N, Ng CY, Tan NS, Yang Z, Hemmings BA, Desvergne B et al (2005) Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor β/δ during hair follicle development. Mol Cell Biol 25:1696–1712PubMedCentralPubMedCrossRef
22.
Eichenfield LF, McCollum A, Msika P (2009) The benefits of sunflower oleodistillate (SOD) in pediatric dermatology. Pediatr Dermatol 26:669–675PubMedCrossRef
23.
Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE et al (1996) Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 224:431–437PubMedCrossRef
24.
Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC et al (2000) Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 136:609–616PubMedCrossRef
25.
Elmongy NN, Shaker O (2012) Expression of peroxisome proliferator activator receptor β/δ in acne vulgaris. Eur J Dermatol 22:42–45PubMed
26.
Freudlsperger C, Moll I, Schumacher U, Thies A (2006) Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anticancer Drugs 17:325–332PubMedCrossRef
27.
Friedmann PS, Cooper HL, Healy E (2005) Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm Venereol 85:194–202PubMedCrossRef
28.
Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J et al (2001) Peroxisome proliferator activated receptor gamma activators affect the maturation of human monocyte derived dendritic cells. Eur J Immunol 21:2857–2862CrossRef
29.
Grabacka M, Placha W, Plonka PM, Pajak S, Urbanska K, Laidler P, Slominski A (2004) Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 296:54–58PubMedCrossRef
30.
Hack K, Reilly L, Palmer C, Read KD, Norval S, Kime R et al (2012) Skin targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ mediated psoriasis-like skin disease. PLoS One 7:e37097PubMedCentralPubMedCrossRef
31.
Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S (2004) Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized controlled trial. Ann Intern Med 140:786–794PubMedCrossRef
32.
Hanley K, Kömüves LG, Bass NM, He SS, Jiang Y, Crumrine D et al (1999) Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators. J Invest Dermatol 113:788–795PubMedCrossRef
33.
Harris SG, Phipps RP (2001) The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 31:1098–1105PubMedCrossRef
34.
Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Elias PM et al (2010) Murine atopic dermatitis responds to peroxisome proliferator activated receptor α, β/δ (but not γ), and liver-X-receptor activators. J Allergy Clin Immunol 125:160–169PubMedCentralPubMedCrossRef
35.
Icre G, Wahli W, Michalik L (2006) Functions of the peroxisome proliferator-activated receptor (PPAR) α and β in skin homeostasis, epithelial repair, and morphogenesis. J Investig Dermatol Symp Proc 11:30–35PubMedCrossRef
36.
Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645–650PubMedCrossRef
37.
38.
Kanakasabai S, Cherwae W, Walline CC, Iams W, Adams SM, Bright JJ (2010) Peroxisome proliferator-activated receptor δ agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology 130:572–588PubMedCentralPubMedCrossRef
39.
Kang HY, Chung E, Lee M, Cho Y, Kang WH (2004) Expression and function of peroxisome proliferator-activated receptors in human melanocytes. Br J Dermatol 150:462–468PubMedCrossRef
40.
Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ et al (2009) Loss of PPARγ in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 60:2822–2829PubMedCrossRef
41.
Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD et al (2009) Hair follicle stem cell-specific PPAR-gamma deletion causes scarring alopecia. J Invest Dermatol 129:1243–1257PubMedCentralPubMedCrossRef
42.
Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S et al (2009) The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 206:2079–2089PubMedCentralPubMedCrossRef
43.
Kömüves LG, Hanley K, Jiang Y, Elias PM, Willium ML, Feingold KR (1998) Ligands and activators of nuclear hormone receptors regulate epidermal differentiation during fetal rat skin development. J Invest Dermatol 111:429–433PubMedCrossRef
44.
Kömüves LG, Hanley K, Man MQ, Elias PM, Williams ML, Feingold KR (2000) Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPAR alpha activators restores tissue homeostasis. J Invest Dermatol 115:361–367PubMedCrossRef
45.
Kuenzli S, Saurat JH (2003) Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol 149:229–236PubMedCrossRef
46.
Kuenzli S, Saurat JH (2003) Effect of topical PPARβ/δ and PPARγ agonists on plaque psoriasis. A pilot study. Dermatology 206:252–256PubMedCrossRef
47.
Lajevardi V, Hallaji Z, Daklan S, Abedini R, Goodarzi A, Abdolreza M (2015) The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol 54:95–101PubMedCrossRef
48.
Liu Y, Meng Y, Li H, Li J, Fu J, Liu Y et al (2006) Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375. Med Oncol 23:393–402PubMedCrossRef
49.
Ludtke A, Heck K, Genschel J, Mehnert H, Spuler S, Worman HJ et al (2005) Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone. Diabet Med 22:1611–1613PubMedCrossRef
50.
Man MQ, Barish GD, Schmuth D, Crumrine Y, Barak S, Chang Y et al (2008) Deficiency of PPAR beta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol 128:370–377PubMedCrossRef
51.
Mahgoub D, El Tawdy AM, Metwally D, Manar A, Rashed L (2014) Estmation of peroxisome-proliferator-activated receptor γ gene expression in inflammatory skin diseases: atopic dermatitis and psoriasis. Our Dermatol Online 5:107–112CrossRef
52.
Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE et al (2004) Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol 123:305–312PubMedCrossRef
53.
Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V et al (2002) PPAR activators as anti-inflammatory mediators in human T lymphocytes; implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90:703–710PubMedCentralPubMedCrossRef
54.
Masuda T, Wada K, Nakajima A, Okura M, Kudo C, Kadowaki T et al (2005) Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res 11:4012–4021PubMedCrossRef
55.
Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J et al (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) alpha and PPAR beta mutant mice. J Cell Biol 154:799–814PubMedCentralPubMedCrossRef
56.
Michiels JF, Perrin C, Leccia N, Massi D, Grimaldi P, Wagner N (2010) PPARβ activation inhibits melanoma cell proliferation involving repression of the Wilms’ tumour suppressor WT1. Pflugers Arch 459:689–703PubMedCentralPubMedCrossRef
57.
Mirmirani P, Karnik P (2009) Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist. Arch Dermatol 145:1363–1366PubMedCentralPubMedCrossRef
58.
Montagner A, Wahli W (2013) Contributions of peroxisome proliferator-activated receptor β/δ to skin health and disease. Biomol Concepts 4:53–64PubMedCrossRef
59.
Mossner R, Schulz U, Kruger U, Middel P, Schinner S, Fuzesi L et al (2002) Agonists of peroxisome proliferator-activated receptor γ inhibit cell growth in malignant melanoma. J Invest Dermatol 119:576–582PubMedCrossRef
60.
Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL et al (2007) Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 21:47–57PubMedCrossRef
61.
62.
Nencioni A, Grunebach F, Zobywlaski A, Denzlinger C, Brugger W, Brossart P (2002) Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol 169:1228–1235PubMedCrossRef
63.
Nicol CJ, Yoon M, Ward JM, Yamashita M, Fukamachi K, Peters JM et al (2004) PPAR{gamma} influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 25:1747–1755PubMedCrossRef
64.
Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, Van Marck E, Lambert J (2004) Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 151:837–845PubMedCrossRef
65.
Nijsten T, Geluyckens E, Colpaert C, Lambert J (2005) Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol 32:340–347PubMedCrossRef
66.
Owen KR, Donohoe M, Ellard S, Hattersley AT (2003) Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabetic Med 20:823–827PubMedCrossRef
67.
Panigrahy D, Shen LQ, Kieran MW, Kaipainen A (2003) Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 12:1925–1937PubMedCrossRef
68.
Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ et al (2002) PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923–932PubMedCentralPubMedCrossRef
69.
Pasceri V, Wu HD, Willerson JT, Yeh ET (2000) Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101:235–238PubMedCrossRef
70.
Pershadsingh HA, Sproul JA, Benjamin E, Finnegan J, Amin NM (1998) Treatment of psoriasis with troglitazone therapy. Arch Dermatol 134:1304–1305PubMedCrossRef
71.
Placha W, Gil D, Dembinska-Kiec A, Laidler P (2003) The effect of PPAR gamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13:447–456PubMedCrossRef
72.
Plager DA, Leontovich AA, Henke SA, Davis MD, McEvoy MT, Sciallis GF 2nd et al (2007) Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Exp Dermatol 16:28–36PubMedCrossRef
73.
Raboud JM, Dlong C, Carr A, Grinspoon S, Mulligan K, Sutinen J et al (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11:39–50PubMedCentralPubMedCrossRef
74.
75.
Romanowska M, Reilly L, Palmer CN, Gustafsson MC, Foerster J (2010) Activation of PPAR β/δ causes a psoriasis-like skin disease in vivo. PLoS One 5:e9701PubMedCentralPubMedCrossRef
76.
Rosenfield RL, Deplewski D, Kentsis A, Ciletti N (1998) Mechanisms of androgen induction of sebocyte differentiation. Dermatology 196:43–46PubMedCrossRef
77.
Rosenfield RL, Kentsis A, Deplewski D, Ciletti N (1999) Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 112:226–232PubMedCrossRef
78.
Rühl R, Dahten A, Schweigert FJ, Herz U, Worm M (2003) Inhibition of IgE-production by peroxisome proliferator-activated receptor ligands. J Invet Dermatol 121:757–764CrossRef
79.
Shafiq N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K (2005) Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 44:328–333PubMedCrossRef
80.
Schamitt JI, Zhang Z, Wozel G, Meurer M, Kirch W (2008) Efficacy and tolerability of biologic and non-biologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 159:513–526CrossRef
81.
Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, Chang S et al (2004) Peroxisome proliferator-activated receptor (PPAR)-β/δ Stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 122:971–983PubMedCrossRef
82.
Schmuth M, Moosbrugger-Martinz V, Blunder S, Dubrac S (2014) Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation. Biochim Biophys Acta 1841:463–473PubMedCrossRef
83.
Schmuth M, Schoonjans K, Yu QC, Fluhr JW, Crumrine D, Hachem JP et al (2002) Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero. J Invest Dermatol 119:1298–1303PubMedCrossRef
84.
Schuster M, Zouboulis CC, Ochsendorf F, Muller J, Thaci D, Bernd A et al (2011) Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne? Br J Dermatol 164:182–186PubMedCrossRef
85.
Sertznig P, Reichrath J (2011) Peroxisome proliferator-activated receptors (PPARs) in dermatology. Challenge and promise. Derm Endocrinol 3:130–135CrossRef
86.
Sertznig P, Seifert M, Tilgen W, Reichrath J (2008) Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases. Am J Clin Dermatol 9:15–31PubMedCrossRef
87.
Sher T, Yi HF, McBride OW, Gonzalez FJ (1993) cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32:5598–5604PubMedCrossRef
88.
Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ (2010) Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology 49:259–263PubMedCrossRef
89.
Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekatjirt A et al (2008) Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 13:67–76PubMed
90.
Smith KJ, Dipreta E, Skelton H (2001) Peroxisomes in dermatology. Part II. J Cutan Med Surg 5:315–322PubMedCrossRef
91.
Staumont-Sallé D, Abboud G, Brénuchon C, Kanda A, Roumier T, Lavogiez C et al (2008) Peroxisome proliferatoractivated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121:962–968PubMedCrossRef
92.
93.
Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Halavaara J, Jarvinen A et al (2003) Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 8:199–207PubMed
94.
Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M et al (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15:3263–3677PubMedCentralPubMedCrossRef
95.
Thieringer R, Fenyk-Melody JE, Le Grand CB, Shelton BA, Detmers PA, Somers EP, Carbin L et al (2000) Activation of peroxisome proliferator activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharides in vitro or in vivo. J Immunol 164:1046–1054PubMedCrossRef
96.
Thuillier P, Anchiraico GJ, Nickel KP, Maldve RE, Gimenez-Conti I, Muga SJ et al (2000) Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol Carcinog 29:134–142PubMedCrossRef
97.
Tirado-Sanchez A, Santamaria-Roman A, Ponce-Olivera RM (2009) Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol 48:893–895PubMedCrossRef
98.
Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilla LL, Sivarajah S et al (2006) Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 2006(126):2002–2009CrossRef
99.
Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S (2011) The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2:236–240PubMedCentralPubMedCrossRef
100.
Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A et al (2003) Antiangiogenic therapy with pioglitazone, rofecoxib and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98:2251–2256PubMedCrossRef
101.
Wahli W (2002) Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly 132:83–91PubMed
102.
Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD et al (2001) Modulation of keratinocyte gene expression and differentiation by PPAR selective ligands and tetradecylthioacetic acid. J Invest Dermatol 116:702–712PubMedCrossRef
103.
Wiechers JW, Rawlings AV, Garcia C, Chesne C, Balaguer P, Corre S et al (2005) A new mechanism of action for skin whitening agents: binding to the peroxisome proliferators-activated receptor. Int J Cosmet Sci 27:123–132PubMedCrossRef
104.
Wróbel A, Seltmann H, Fimmel S, Müller-Decker K, Tsukada M, Bogdanoff B et al (2003) Differentiation and apoptosis in human immortalized sebocytes. J Invest Dermatol 120:175–181PubMedCrossRef
105.
Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J (2009) Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator activated receptor-gamma. Am J Pathol 174:519–533PubMedCentralPubMedCrossRef
106.
Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116–9121PubMedCrossRef
107.
108.
Yessofou A, Wahli W (2010) Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly 140:w13071
109.
Yilmaz M, Karakoc A, Toruner FB, Cakir N, Tiras B, Ayvaz G et al (2005) The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 21:154–160PubMedCrossRef
110.
Zoete V, Grosdidier A, Michielin O (2007) Peroxisome proliferator activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochem Biophys Acta 1771:915–925PubMed
111.
Metadata
Title
Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the ‘future’ in dermatology therapeutics?
Authors
Mrinal Gupta
Vikram K. Mahajan
Karaninder S. Mehta
Pushpinder S. Chauhan
Ritu Rawat
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 9/2015
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-015-1571-1

Other articles of this Issue 9/2015

Archives of Dermatological Research 9/2015 Go to the issue

Original Paper

Pseudoceramide stimulates peroxisome proliferator-activated receptor-α expression in a murine model of atopic dermatitis: molecular basis underlying the anti-inflammatory effect and the preventive effect against steroid-induced barrier impairment

Concise Communication

N1-methylspermidine, a stable spermidine analog, prolongs anagen and regulates epithelial stem cell functions in human hair follicles

Concise Communication

Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid

Original Paper

Alcohol consumption and risk of melanoma among women: pooled analysis of eight case–control studies

Original Paper

Incidence of adverse cutaneous drug reactions in 22,866 Chinese inpatients: a prospective study

Original Paper

Intracellular signaling pathways involved in the release of IL-4 and VEGF from human keratinocytes by activation of kinin B1 receptor: functional relevance to angiogenesis